KPV
10mg · Lyophilised powder
Stability-tested KPV supplied as a sterile 10 mg lyophilised vial for in-vitro study.
KPV 10MG (Lysine-Proline-Valine) is a high-purity research tripeptide intended exclusively for laboratory and scientific research use. KPV is a three-amino-acid peptide fragment derived from the C-terminal region of alpha-melanocyte-stimulating hormone (α-MSH). It has been investigated in experimental research involving inflammatory signalling, immune-response pathways, epithelial biology, and cellular homeostasis. Its mechanisms of action and wider biological significance remain subjects of ongoing scientific investigation.
Product Features
- Strength: 10 mg per vial
- Form: Lyophilized (freeze-dried) powder
- Sequence: Lysine-Proline-Valine (KPV)
- High-purity research-grade peptide
- Manufactured under strict quality control standards
- Sterile, securely sealed vial
Research Applications
KPV is commonly investigated in laboratory studies involving:
- Inflammatory signalling pathways
- Immune-response mechanisms
- Epithelial and cellular barrier biology
- Gastrointestinal tissue research
- Skin and dermatological research models
- Cellular homeostasis and oxidative stress pathways
- Compound
- KPV
- Strength
- 10mg
- Form supplied
- Lyophilised powder
- Research areas
- Research Peptides
- Storage
- Store lyophilised material refrigerated between 2–8°C (Celsius), cold and dark, protected from light and moisture.
- Batch reference
- Stated on the vial label at dispatch
- Analytical documentation
- No analytical document is currently held for this batch. Where documentation is held it is published here.
Specification
Research-use notice
All products supplied by The Peptide Kings are sold strictly for laboratory research use only. They are not medicines, not dietary supplements, and are not intended for human or veterinary consumption or administration. Information published on this website is provided for educational and scientific reference purposes only and must not be interpreted as medical advice.